Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Capricor Therapeutics stock | $5.18
Own Capricor Therapeutics stock in just a few minutes.
Capricor Therapeutics, Inc is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Capricor Therapeutics employs 16 staff and has a trailing 12-month revenue of around USD$599,728.
How to buy shares in Capricor Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Capricor Therapeutics Find the stock by name or ticker symbol: CAPR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Capricor Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$5.18, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Capricor Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Capricor Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
How has coronavirus impacted Capricor Therapeutics's share price?
Since the stock market crash in March caused by coronavirus, Capricor Therapeutics's share price has had significant positive movement.
Its last market close was USD$5.18, which is 73.17% up on its pre-crash value of USD$1.39 and 488.64% up on the lowest point reached during the March crash when the shares fell as low as USD$0.88.
If you had bought USD$1,000 worth of Capricor Therapeutics shares at the start of February 2020, those shares would have been worth USD$773.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,453.35.
Capricor Therapeutics share price
Use our graph to track the performance of CAPR stocks over time.Capricor Therapeutics shares at a glance
Information last updated 2020-09-20.
| Latest market close | USD$5.18 |
|---|---|
| 52-week range | USD$0.88 - USD$12.32 |
| 50-day moving average | USD$5.8765 |
| 200-day moving average | USD$4.5322 |
| Wall St. target price | USD$10.5 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-3.736 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Capricor Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Capricor Therapeutics price performance over time
Historical closes compared with the last close of $5.18
| 1 week (2020-09-14) | -3.54% |
|---|---|
| 1 month (2020-08-21) | -12.94% |
| 3 months (2020-06-19) | 4.86% |
| 6 months (2020-03-20) | 366.67% |
| 1 year (2019-09-20) | 67.64% |
|---|---|
| 2 years (2018-09-21) | 379.63% |
| 3 years (2017-09-21) | 159.00% |
| 5 years (2015-09-21) | 15.11% |
Capricor Therapeutics financials
| Revenue TTM | USD$599,728 |
|---|---|
| Gross profit TTM | USD$-4,136,777 |
| Return on assets TTM | -24.49% |
| Return on equity TTM | -50.83% |
| Profit margin | 0% |
| Book value | $1.607 |
| Market capitalisation | USD$109.7 million |
TTM: trailing 12 months
Shorting Capricor Therapeutics shares
There are currently 442,735 Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 61.5% up from 274,188 last month.
There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.
Capricor Therapeutics's "short interest ratio" (SIR)
Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 574980.51948052). Capricor Therapeutics's SIR currently stands at 0.77. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 770 shares are currently held short.
However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 100 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.
Find out more about how you can short Capricor Therapeutics stock.
Capricor Therapeutics share dividends
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Have Capricor Therapeutics's shares ever split?
Capricor Therapeutics's shares were split on a 1:10 basis on 5 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Capricor Therapeutics share price volatility
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $0.88 up to $12.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.9359. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Frequently asked questions
Ask an Expert